Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP: RHHBF )

287.11 -0.00 (-0.00%)
Streaming Delayed Price Updated: 12:03 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Ltd

< Previous 1 2 3 4 5 6 Next >
Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit
Via Benzinga
Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test
Via Benzinga
New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A
Via Benzinga
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
Via Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
Via Benzinga
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
Via Benzinga
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung... 
Via Benzinga
Roche Releases More Evrysdi Data For Very Young Infants With SMA
Via Benzinga
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine. 
Via Benzinga
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
Via Benzinga
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
Via Benzinga
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was... 
Via Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. 
Via Benzinga
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
Via Benzinga
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults
Via Benzinga
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)  
Via Benzinga
Drug makers, Scientists Working For Long COVID Treatments: Reuters
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
Via Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests
Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH 
Via Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,  
Via Benzinga
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
Biogen Inc (NASDAQ: BIIB) has  
Via Benzinga
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo
The FDA has approved Genentech's, a unit of  
Via Benzinga
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (... 
Via Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
Via Benzinga
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)... 
Via Benzinga
Novartis Launches New Share Buyback Program Of Up To $15B
Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.